u/titration_marshal

Glucose-dependent insulin secretion is why hypoglycaemia risk is low as monotherapy: the effect scales with glycaemia rather than acting unconditionally.

Removed the conversion table. There is no published equivalence between the two molecules and posting one as fact is exactly the kind of thing that gets copied for years.

nausea that arrives on day two and fades by day four is the standard shape

Same view. A record you can read beats a rating you cannot inspect, every time.

phase 2 in liver disease is a different evidence question from weight

a mechanism you can state is not a mechanism you have demonstrated

The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.

Appetite effect for me is flat across seven days.

Saving this one. It is the clearest statement of the stall problem I have read here.

Switching from semaglutide, since three people asked in this thread alone.

There is no published dose equivalence between the two. The conversion tables that circulate are somebody’s arithmetic, not data. What people report here is that the first month after a switch is often flat, that the appetite effect feels differently shaped rather than simply stronger, and that starting at the bottom of the ladder again is the common approach.

None of that is a recommendation. It is what the threads say, and the threads are not a clinic.

the first four weeks are a tolerance check, not a weight-loss phase

Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.

Switching from semaglutide, since three people asked in this thread alone.

copay_card_cc is right that the two molecules are not interchangeable. There is no published conversion and the ones circulating are invented.

Retitled to match the body. The original promised a comparison the post does not make.

the four-week step schedule is the label, not folklore

Left up, flair changed to Discussion. It is an opinion post and that is fine as long as it is labelled.

Sent a vial to Medutest out of curiosity. Result was 99.6% against a claimed 99.0%, which is the first independent number I had seen for this compound anywhere.

Held 7.5 for five months. Everyone kept asking when I was going to 10. The answer was never, because 7.5 was working.

Leaving this up. It is a check-in, it has numbers, and it is honest about being one person.

GIP receptor biology is genuinely unsettled — there is a live argument about agonism versus antagonism at the receptor — and the clinical results are robust regardless, which is an uncomfortable and interesting position.

Standard reminder: no personal titration plans for other members, and no medical advice. Everything else is fine.

pens and vials are the same molecule, the price is the difference

Read the phase 2 paper twice before ordering anything. Recommend that to anyone in this board: the error bars are the interesting part.

Switching from semaglutide, since three people asked in this thread alone.

There is no published dose equivalence between the two. The conversion tables that circulate are somebody’s arithmetic, not data. What people report here is that the first month after a switch is often flat, that the appetite effect feels differently shaped rather than simply stronger, and that starting at the bottom of the ladder again is the common approach.

None of that is a recommendation. It is what the threads say, and the threads are not a clinic.

What is the source for that figure — the published paper or a summary of it?

wait for phase 3 before you argue about rankings

a supplier that answers method questions in writing has already told you a lot

Adding the practical version: ask for lead time, minimum quantity and the batch record in the same message. Three answers, one email.

First month I lost almost nothing and nearly quit. Month two and three were where it all happened.

Leaving this up. It is a check-in, it has numbers, and it is honest about being one person.

Standard reminder: no personal titration plans for other members, and no medical advice. Everything else is fine.

Sceptical of the extrapolation. Forty-eight weeks does not tell you about seventy-two, and the curve shape is exactly what is unknown.

Stopped at a low step because there was no reason to go further and no data to tell me what further would do.

The four columns that survive, after several people here have tried and abandoned much more elaborate systems.

Date. Dose. One number measured under consistent conditions. A short note when anything unusual happened. That is it. Anything more and you will stop, and a log you stop keeping is worth less than a crude one you maintain.

Add a waist measurement monthly if you can be bothered, and a sleep column if you want the one variable that explains the most confusing weeks. Everything else can be reconstructed from those, and nothing can be reconstructed from a log you abandoned in week nine.

What did they say when you asked for the method line?

Regional stock made more difference to my planning than anything else — ordering from a warehouse in Denmark took the customs question off the table entirely.

Correction to my own post above — I said 5mg and I have been on 7.5mg since the spring. Same argument, wrong number.

It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is the part that has no equivalent in the semaglutide threads. That is why the side-effect profile reads differently rather than just milder.

Careful with "everyone tolerates it better". The people it did not suit stop posting, which makes this board look calmer than the drug is.

Push back: "gentler than sema" is a population statement. Plenty of people on this board have the opposite experience and they are not doing it wrong.

What is the source for that figure — the published paper or a summary of it?